CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...

The agreements cap monthly out-of-pocket costs for Zepbound and Wegovy at $200 and more deeply discount the drugs for ...

Allison Stange lost 40 pounds since starting Zepbound in April 2024, improving both her blood pressure and sleep apnea. Now she fears a deal struck between CVS Health Corp. and Novo Nordisk A/S will ...

The Cigna Group (NYSE:CI)’s Evernorth division has announced a new deal with Novo Nordisk and Eli Lilly that will limit ...

Evernorth said that through direct negotiations with Novo Nordisk and Eli Lilly, patients’ monthly copay costs for Wegovy ...

CVS Caremark to list Wegovy as preferred GLP-1 drug on top formularies starting July 1, 2025. Novo Nordisk plans continued collaboration with CVS to widen Wegovy access. Get Matt Maley’s top ...

CVS Caremark has selected Novo Nordisk’s Wegovy as the preferred GLP-1 medication for its largest commercial template formularies, effective July 1. In March, Novo Nordisk launched NovoCare ...

Wegovy ® will be the preferred GLP-1 medicine for obesity on the largest commercial template formularies for CVS Caremark, the largest Pharmacy Benefit Manager (PBM) in the US, effective July 1 ...

CVS’ pharmacy benefit manager Caremark also reached an agreement with Danish drugmaker Novo Nordisk to give its weight loss drug Wegovy preferred access on Caremark’s standard formulary ...

Starting July 1, Wegovy will become the preferred GLP-1 for obesity treatment on CVS Caremark’s largest commercial template formularies, Novo said Thursday. CVS Caremark, which forms the ...

Cigna’s pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.